Compare Innodata Inc (INOD) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innodata Inc vs Zoetis Inc — how do they compare? Innodata Inc trades at $64 (market cap $2.03B), while Zoetis Inc trades at $75.64 (market cap $31.95B). The key difference: Zoetis Inc is far larger — about 15.7× Innodata Inc's market cap, and Zoetis Inc pays a 2.78% dividend while Innodata Inc pays none. Which is the better fit depends on your goals.
| INOD | ZTS | |
|---|---|---|
Market Cap | $2.03B | $31.95B |
Sector | Technology | Health |
52-Week High | $121.50 | $156.76 |
52-Week Low | $34.45 | $71.91 |
Enterprise Value | $1.91B | $39.24B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INOD trades at $62.08, up 2.09% today, showing strong momentum despite a bearish technical signal. The company demonstrates robust fundamentals with revenue growth from $252M in 2025 to $283M projected for 2026, and net income margins improving to 13.86%. Recent earnings beats and positive AI-driven news highlight growing demand for its engineering R&D services. Technical indicators show mixed signals with RSI suggesting oversold conditions but moving averages indicating bearish pressure.
Outlook remains positive with 60% analyst buy ratings and a $130 consensus price target representing 109% upside. Key opportunities include AI market expansion and customer diversification, while risks center on high valuation multiples (P/E 54.29) and customer concentration. The stock's recent 33% pullback may present a buying opportunity for growth-oriented investors.
Zoetis (ZTS) trades at $76.05, down 0.67% on the day, with a neutral technical signal and bearish moving averages. The company maintains strong fundamentals with a 28.03% net income margin and 67.75% ROE, though Q1 2026 earnings missed expectations. Recent news highlights multiple securities class action lawsuits filed against the company, creating near-term uncertainty despite the launch of new product Lenivia in Canada and EU markets.
The stock presents a mixed outlook with attractive valuation metrics (P/E 12.55) and analyst consensus price target of $101.43 suggesting 33% upside potential. However, legal challenges and the recent earnings miss pose significant near-term risks. Institutional sentiment remains divided with 47% buy ratings versus 53% hold ratings, indicating cautious optimism amid legal headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
